Perioperative Insulin Glargine Dosing Study

PHASE4CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2009

Conditions
DiabetesSurgery
Interventions
DRUG

Lantus

Patients in Group 1 will administer 80% of their usual insulin glargine dose.

OTHER

Insulin

Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose

DRUG

Lantus

Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.

Trial Locations (2)

48073

William Beaumont Hospital, Royal Oak

48085

William Beaumont Hospital, Troy

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Tamra Dukatz

OTHER

NCT00309465 - Perioperative Insulin Glargine Dosing Study | Biotech Hunter | Biotech Hunter